Atlas Trials

Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD

Clinical trial NCT06924710 · RECRUITING

Trial details

NCT number
NCT06924710
Sponsor
Peking University Cancer Hospital & Institute
Status
RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
NSCLC
Start date
2025-04-06
Primary completion
2029-06-15
Enrollment
286

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.